CAPE TOWN, SA / ACCESSWIRE / September 17, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:

M2Bio Sciences Food and Beverage is thrilled to launch the Medspresso CBD Infused Organic Whole Bean and Ground Coffee Range. The range will consist of two Speciality Coffees: the Mbeya Tanzanian Peaberry single-origin and the Estate Ethiopian & Kenyan Blend. Speciality coffee is defined as any coffee that scores above 80 points on a 100 point scale. Typically, speciality coffee is grown at high altitudes, with much care and attention from the farmer.

As a result of the Covid-19 pandemic, consumers, both globally and locally, are looking for ways to improve their at-home coffee experience, as well as continuing to enjoy their favourite coffee drinks, without having to leave their homes.

The global coffee market was valued at approximately $465 billion in 2020. Furthermore, the market is expected to increase at a compound annual growth rate (CAGR) of approximately 6.2%, to reach a value of approximately $668 billion by 2026.

"We are thrilled to add the Speciality Whole Bean and Ground range to our coffee selection. The demand for our existing coffee products has been phenomenal, and consumer feedback has been nothing short of exceptional. This stunning response expedited our decision to launch the new Speciality Whole Bean and Ground range sooner than anticipated. We chose the Mbeya Tanzanian Peaberry bean for its wide flavour profile, light acidity and strong notes of chocolate and blackcurrant. The Estate Ethiopian & Kenyan blend is a superb balance of spicy and sweet flavours, with a smooth mouthfeel, elevating this blend to something truly extraordinary" said Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

The coffees are skillfully roasted by Gerald Charles of Rock & Roller Coffee Culture. "Doctor G" as he is affectionately known in the coffee community is recognised by SCASA (Specialty Coffee Association of Southern Africa) as one of the leading coffee technicians in South Africa, and has had numerous championship-winning baristas pass through his stable.

"The infusion process is fascinating to say the least. Weighty floral aromas take over the entire roasting space. As the coffee cools down during the roasting process, we hold the temperature at 65 degrees Celsius and infuse the CBD, thereby ensuring a consistent, even infusion. The taste experience is overwhelmingly calming and invigorating at the same time " said Charles.

The Mbeya Tanzanian Peaberry and the Estate Ethiopian & Kenyan blend will be available in Whole Bean, Espresso Ground and Filter Ground, and will be on the shelves from November 1st 2021.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2Bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".

For further information:

Publicly traded company (OTC Pink:WUHN)

Follow us on Twitter:
Follow us on Instagram:
Follow us on Facebook:

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.

View source version on